Background: This study details the long-term management of severe case of canine atopic dermatitis (CAD) in an eight-year-old male Beagle dog with a three-year history of recurrent pruritus responsive to corticosteroids. Diagnosis was based on clinical presentation, fulfillment of all eight Favrot&rsquo;s criteria and exclusion of other differentials. 
 
Methods: Lokivetmab was administered subcutaneously at 2 mg/kg every 30 days over 12 months following a test dose with no adverse effects. Disease severity was assessed at 30-day intervals using CADESI-04, Pruritus Visual Analogue Scale (PVAS), Erythema Severity Score (ESS), dermatoscopic erythema index (EIRGB) and hemato-biochemical analysis. 
 
Result: Pruritus resolved within the first 30 days but re-emerged thereafter, necessitating monthly dosing. CADESI-04 scores decreased from 91 at baseline to 59 by Day 120 and remained stable through Day 360. There was a drastic reduction in erythema with partial or complete lesion resolution in most sites. PVAS scores declined by &ge;50% and ESS reduced from 3 to 1. Dermatoscopy supported these findings. Hematological and biochemical parameters remained within normal limits throughout.

Long Term Use of Lokivetmab Monotherapy and its Expression in a Beagle with Severe Atopic Dermatitis: First Clinical Study from India

Background: Canine atopic dermatitis (CAD) often develops skin problems and produce immunoglobulin E (IgE) against environmental allergens. Interleukin-31 (IL-31) is an important itch-inducing cytokine in human atopic dermatitis (AD). The study aimed to quantify serum IL-31 and total IgE in CAD-affected dogs and to evaluate their correlation with disease severity. 
&nbsp; 
Methods: Twelve client-owned dogs with CAD were enrolled after diagnosis based on favrot&rsquo;s criteria. Six apparently healthy dogs were included as the healthy control group. The severity of cutaneous lesions was assessed using the canine atopic dermatitis extent and severity index-04 (CADESI-04) scoring system. Pruritus intensity was evaluated using the pruritus visual analog scale (pVAS). Serum IL-31 and total IgE levels were assessed using canine-specific commercial sandwich ELISA kits (FineTest&reg;, Wuhan, China). 
&nbsp; 
Result: Dogs with CAD exhibited significantly increased serum IL-31 concentrations compared with healthy controls (p = 0.001). Likewise, total IgE levels were markedly higher in the CAD group than in the control group (p = 0.010). A strong positive association was observed between serum IL-31 levels and pVAS scores (Spearman&rsquo;s rank correlation, &rho; = 0.804; p = 0.003). The study highlights the diagnostic and clinical relevance of serum IL-31 and total IgE as potential biomarkers in CAD.

Assessment of Serum Interleukin-31 and Total Immunoglobulin E Concentrations and Their Correlation with Disease Severity in Canine Atopic Dermatitis